Participated · Seed · Jul 2024

ByBug develops a platform that expresses recombinant proteins in genetically engineered black soldier fly (BSF) larvae as an alternative to precision fermentation. The company says this approach can lower upstream costs—claiming BSF rearing is 10–20× cheaper than microbial fermentation—due to cheaper feedstock, lower capex, and lower labor. ByBug operates an R&D center in Chile with a semi‑industrial BSF rearing plant and molecular biology lab, and has established a commercial office in Tulsa, Oklahoma. Its product pipeline includes unpurified high‑protein insect flour containing recombinant proteins and purified recombinant proteins; downstream processing and purification remain under development. The firm also plans to monetize byproducts such as animal‑feed biomass, frass fertilizer, and fatty acids for cosmetics. ByBug has two patent applications pending for a BSF strain transportation system and a genetic‑editing methodology for insects.

Participated · Seed · May 2024

Volt provides a centralized API and Messaging Operations infrastructure that lets software companies integrate with multiple SMS providers, manage phone-number registration across carriers, and surface real-time deliverability insights. The platform reduces engineering hours spent on maintaining SMS compliance and delivery tooling and guides brands through carrier registration hurdles. Volt has partnered with major programmable-communications providers including Twilio, Vonage, Telnyx, and Bandwidth, and has processed nearly half a billion messages on its platform. The company reports operational profitability and revenue growth of over 100% in Q1 2024. Launched in mid-2022 and based in Tulsa, Oklahoma, Volt plans to use new funding to accelerate product development and strategically expand its team. Leadership emphasizes scaling capabilities, driving awareness around Messaging Ops, and tackling additional opportunities within the space.

Participated · Series A · Feb 2024

Founded in 2021 by CEO Aniq Rahman, Florence develops a healthcare enablement platform that lets patients manage their care journey from their smartphones, including updating clinical information, controlling prescription fulfillment, initiating self-discharge when appropriate, and scheduling follow-up appointments. The software is designed to improve efficiency across varied sites of care, starting with emergency departments. Florence is already collaborating with health systems and recently deployed its solution with Luminis Health in Maryland. The company positions itself as a comprehensive patient-engagement layer that can shorten care timelines and reduce administrative burdens. With its recent capital infusion, Florence plans to accelerate growth, broaden its operational footprint, and deepen its presence with additional health-system partners. No specific revenue, user, or customer metrics were disclosed in the article. The company’s near-term focus is on scaling product capabilities and expanding market reach within the U.S. healthcare system.

Participated · Series B · Oct 2023

Optimize Health is a Seattle-based provider of a remote patient monitoring and chronic care management software platform. Led by CEO Todd Haedrich, the company’s platform helps healthcare providers improve patient outcomes, enhance clinical decision-making, and optimize operational efficiency. Its technology assists physicians in preventing episodic events, delivering personalized care plans, and enabling clinical teams to practice proactive medicine by sharing patient data and insights. The platform also empowers patients with visibility into their health metrics to increase engagement. Thousands of healthcare providers have used the software to drive down costs and create better outcomes. The company plans to use new funding to accelerate market strategy, scale operations, expand its product portfolio, and fuel market expansion. Optimize Health recently closed an $18M Series B financing. Founded in 2015 and based in Seattle, Optimize.health offers an end-to-end remote patient monitoring service used by independent practices and hospital systems. The platform ingests data from home devices such as blood pressure cuffs and pulse oximeters, surfaces potential issues on a clinician dashboard, integrates with EHRs, and supports outreach via texts and video calls. The dashboard can trigger billing to insurers for clinician monitoring. The company shifted from its prior Pillsy smart pill-bottle product to a broader remote-monitoring strategy. Optimize.health is capitalizing on a recent Medicare policy change that allows providers to bill for remote monitoring and on increased attention to telemedicine amid the pandemic. Revenue recently grew more than 800% year-over-year; the company employs fewer than 30 people and has raised over $21 million to date. optimize.health offers a technology platform that enables healthcare providers to deliver patient-centric, reimbursable remote monitoring using a wide selection of integrated, affordable devices. The solution integrates device data with the company’s platform to help patients and providers improve health outcomes and contain costs. The company plans to use new funding to build out platform capabilities and integrate additional data sources, and to expand its sales and marketing teams. optimize.health was established in 2019 by Jeff LeBrun and Chuks Onwuneme and is based in Seattle with additional employees in Phoenix, Houston and Charlotte, NC. Its team and advisors include clinicians, software engineers, designers and data scientists with backgrounds at Google, Microsoft, Apple, Facebook, Amazon, Novartis, Duke University and the Institute for Health Metrics.

Led · Series A · Aug 2023

PatchRx is a patient-focused medication management platform that pairs a patented universal smart pill bottle device with a provider web app and on-staff nurses to deliver personalized support. The company aims to improve outcomes through connected technologies and medication adherence services. Its patented technology has been deployed in over 40 clinics across the U.S., from Alaska to New Jersey. In 2022 PatchRx began offering a medication adherence platform under new Medicare RTM billing codes. The company is pursuing expansion beyond pain management into clinical trials and psychiatric markets. PatchRx expanded headcount from about 10 to 80+ employees and reached $4M in revenue within 12 months.